Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3565MR)

This product GTTS-WQ3565MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3565MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3348MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ178MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ11398MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ12684MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ3506MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ4640MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ2702MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ7795MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GS-HIV
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW